证券记录 · 已归档季度
ZURA
Zura Bio Limited · Healthcare · Biotechnology
16被追踪持有人
+3Δ持有人
16.65M持有股份
$72.09M报告持仓市值
+3新建仓位
−0清仓
动量输入（同类管理人）：
持有人广度 +23.1% ·
股份流向 +7.4% ·
净新建仓位 +18.8%
— 公式
广泛积累 — 持股数量上升且持有人增多
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q2 2026 | 44 | +6 | 19.12M | $111.66M | +15 | −9 |
| Q1 2026 | 39 | +4 | 16.55M | $97.28M | +6 | −2 |
| Q4 2025 | 35 | -1 | 16.01M | $83.89M | — | −1 |
| Q3 2025 | 16 | +3 | 16.65M | $72.09M | +3 | — |
| Q2 2025 | 10 | -1 | 5.96M | $6.26M | — | −1 |
| Q1 2025 | 8 | -1 | 4.76M | $6.14M | +1 | −2 |
| Q4 2024 | 9 | 0 | 5.19M | $12.99M | +1 | −1 |
| Q3 2024 | 8 | +2 | 3.98M | $16.15M | +2 | — |
| Q2 2024 | 6 | — | 3.73M | $12.85M | — | — |
持有人 · Q3 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | JPMorgan Chase ✦ | 9.25M | — | $40.05M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | JPMorgan Chase ✦ | 9.25M | — | $40.05M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | JPMorgan Chase ✦ | 9.25M | — | $40.05M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | JPMorgan Chase ✦ | 9.25M | — | $40.05M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Adage Capital Partners ✦ | 3.05M | 新增 | $13.19M | 0.0% | New | 1 | SEC ↗ |
| 6 | Point72 Asset Management ✦ | 726.33K | -69.1% | $3.15M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 7 | Millennium Management ✦ | 589.70K | -25.3% | $2.55M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 8 | Fidelity (FMR) ✦ | 531.29K | -6.7% | $2.30M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 9 | The Vanguard Group ✦ (被动) | 517.14K | 0.0% | $2.24M | 0.0% | Held | 2 | SEC ↗ |
| 10 | The Vanguard Group ✦ (被动) | 517.14K | 0.0% | $2.24M | 0.0% | Held | 2 | SEC ↗ |
| 11 | The Vanguard Group ✦ (被动) | 517.14K | 0.0% | $2.24M | 0.0% | Held | 2 | SEC ↗ |
| 12 | Geode Capital Management ✦ (被动) | 405.30K | -0.5% | $1.76M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 13 | Geode Capital Management ✦ (被动) | 405.30K | -0.5% | $1.76M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 14 | BlackRock ✦ (被动) | 365.67K | -36.8% | $1.58M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | BlackRock ✦ (被动) | 365.67K | -36.8% | $1.58M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 16 | BlackRock ✦ (被动) | 365.67K | -36.8% | $1.58M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | Marshall Wace ✦ | 267.20K | 新增 | $1.16M | 0.0% | New | 1 | SEC ↗ |
| 18 | Marshall Wace ✦ | 267.20K | 新增 | $1.16M | 0.0% | New | 1 | SEC ↗ |
| 19 | Renaissance Technologies ✦ | 255.40K | +25.1% | $1.11M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 20 | Morgan Stanley ✦ | 209.43K | — | $906,814 | 0.0% | n/c | 1 | SEC ↗ |
| 21 | Morgan Stanley ✦ | 209.43K | — | $906,814 | 0.0% | n/c | 1 | SEC ↗ |
| 22 | Morgan Stanley ✦ | 209.43K | — | $906,814 | 0.0% | n/c | 1 | SEC ↗ |
| 23 | State Street Global Advisors ✦ (被动) | 144.36K | 0.0% | $625,092 | 0.0% | Held | 4 | SEC ↗ |
| 24 | Two Sigma Investments ✦ | 136.30K | -44.4% | $590,192 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 25 | Goldman Sachs Group ✦ | 81.72K | — | $353,860 | 0.0% | n/c | 1 | SEC ↗ |
| 26 | Goldman Sachs Group ✦ | 81.72K | — | $353,860 | 0.0% | n/c | 1 | SEC ↗ |
| 27 | Citadel Advisors ✦ | 80.53K | 新增 | $348,686 | 0.0% | New | 1 | SEC ↗ |
| 28 | AQR Capital Management ✦ | 44.22K | -71.7% | $191,452 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 29 | AQR Capital Management ✦ | 44.22K | -71.7% | $191,452 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 30 | AQR Capital Management ✦ | 44.22K | -71.7% | $191,452 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 31 | AQR Capital Management ✦ | 44.22K | -71.7% | $191,452 | 0.0% | ▼ Trim | 3 | SEC ↗ |
"持仓权重"= 该持仓占该管理人已申报13F股权价值的比例——即信念度衡量指标。✦ = 精选管理人。
新增买入方
| Adage Capital Partners | $13.19M | 0.0% |
| Marshall Wace | $1.16M | 0.0% |
| Marshall Wace | $1.16M | 0.0% |
| Citadel Advisors | $348,686 | 0.0% |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 92 持有人, 61.32M 股份, $364.31M 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
该证券的被追踪持有人最常同时持有的其他证券——基于共同持有计数，而非基本面关联。
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2025 ·
方法论 ·
通过API获取此数据